Literature DB >> 12699364

Cytokine, chemokine, and costimulatory molecule modulation to enhance efficacy of HIV vaccines.

Jeffrey D Ahlers1, Igor M Belyakov, Jay A Berzofsky.   

Abstract

Understanding key intervention points in developing immune responses may allow the rational inclusion of biological adjuvants into vaccines that could potentiate the immune response both quantitatively and qualitatively and enhance effective memory responses. Cytokine and chemokine combinations can potentially help target antigen to the appropriate antigen presenting cell and initiate maturation of these presenting cells, attract cells expressing different chemokine receptors, steer cellular immune responses toward Th1 and CD8 CTL, and enhance systemic and mucosal IgG and secretory IgA antibodies and determine their isotype balance. Animal protection studies suggest that synergistic combinations of cytokines and immunomodulating molecules may be required to protect from a viral challenge. For example, GM-CSF has been shown to be synergistic with IL-12 or CD40 ligand for induction of CTL and for antiviral protection, and the triple combination of GM-CSF, IL-12, and TNF alpha appears to induce the most effective protection in some mouse models. Chemokine-antigen fusions have also been shown to enhance immunogenicity of the antigen. Combinations of costimulatory molecules have been found to be synergistic when incorporated in a vaccine. Combined use of newer more potent vaccine constructs, containing codon optimized epitopes, relevant CpG motifs, cytokines, costimulatory molecules and chemokines, used in heterologous prime-boost strategies with viral vector vaccines or recombinant proteins, might afford the most potent vaccine approaches yet developed. In this review we will discuss the application and delivery of cytokines, costimulatory molecules, and chemokines toward improving current vaccine strategies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12699364     DOI: 10.2174/1566524033479843

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  23 in total

1.  Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells.

Authors:  Igor M Belyakov; Scott A Hammond; Jeffrey D Ahlers; Gregory M Glenn; Jay A Berzofsky
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

Review 2.  Strategies to use immune modulators in therapeutic vaccines against cancer.

Authors:  Jay A Berzofsky; Masaki Terabe; Lauren V Wood
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

3.  Activation of NF-kappaB by the intracellular expression of NF-kappaB-inducing kinase acts as a powerful vaccine adjuvant.

Authors:  E Andreakos; R O Williams; J Wales; B M Foxwell; M Feldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-13       Impact factor: 11.205

4.  Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa.

Authors:  Igor M Belyakov; Vladimir A Kuznetsov; Brian Kelsall; Dennis Klinman; Marcin Moniuszko; Michael Lemon; Phillip D Markham; Ranajit Pal; John D Clements; Mark G Lewis; Warren Strober; Genoveffa Franchini; Jay A Berzofsky
Journal:  Blood       Date:  2005-12-22       Impact factor: 22.113

5.  Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.

Authors:  Geoffrey W Stone; Suzanne Barzee; Victoria Snarsky; Kristin Kee; Celsa A Spina; Xiao-Fang Yu; Richard S Kornbluth
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

6.  Utilizing IL-12, IL-15 and IL-7 as Mucosal Vaccine Adjuvants.

Authors:  Liljana Stevceva; Marcin Moniuszko; Maria Grazia Ferrari
Journal:  Lett Drug Des Discov       Date:  2006       Impact factor: 1.150

7.  Effects of fungal N- and O-linked mannosylation on the immunogenicity of model vaccines.

Authors:  Michael Luong; Jennifer S Lam; Jianmin Chen; Stuart M Levitz
Journal:  Vaccine       Date:  2007-03-30       Impact factor: 3.641

Review 8.  Viral vaccines and CTL response.

Authors:  Stacie N Woolard; Uday Kumaraguru
Journal:  J Biomed Biotechnol       Date:  2010-03-31

Review 9.  Progress on new vaccine strategies against chronic viral infections.

Authors:  Jay A Berzofsky; Jeffrey D Ahlers; John Janik; John Morris; SangKon Oh; Masaki Terabe; Igor M Belyakov
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

10.  Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses.

Authors:  James T Snyder; Igor M Belyakov; Amiran Dzutsev; François Lemonnier; Jay A Berzofsky
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.